找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Handbook of Relapsing-Remitting Multiple Sclerosis; Aaron Miller Book 2017 Springer International Publishing Switzerland 2017 Demyelinatio

[復(fù)制鏈接]
樓主: JAR
31#
發(fā)表于 2025-3-26 22:04:26 | 只看該作者
Multiple Sclerosis: An Overview,of any one particular field. Nowhere is this challenge more manifest than in the field of multiple sclerosis (MS), where advances in basic science, neuroimaging, and clinical care have shaped a landscape that might have seemed unrecognizable to neurologists practicing 50 years ago. The Handbook of R
32#
發(fā)表于 2025-3-27 02:26:26 | 只看該作者
The Pathophysiology and Clinical Presentation of Multiple Sclerosis,ibed in great detail. Nonetheless, the specific etiology and a unifying pathophysiologic mechanism linking the relapsing and progressive aspects of the disease elude us. In this chapter, we review current hypotheses regarding the etiology of MS, the pathologic cascade underlying MS relapse, the immu
33#
發(fā)表于 2025-3-27 05:47:10 | 只看該作者
Assessment and Diagnosis of Relapsing Multiple Sclerosis,(RRMS) has remained the same, requiring evidence of disease dissemination at various time points and in various parts of the central nervous system (dissemination in time and space). Criteria for dissemination can be fulfilled either by clinical relapses or, more recently, by characteristic MRI abno
34#
發(fā)表于 2025-3-27 12:01:21 | 只看該作者
Treatment Strategies in Multiple Sclerosis,countries. Disease-modifying therapies (DMTs) for MS are primarily aimed at reducing relapse rate and disability accumulation over time, and have been shown to significantly decrease disease activity clinically as well as radiographically on MRI. In the past several years, the number of therapies fo
35#
發(fā)表于 2025-3-27 13:55:50 | 只看該作者
Emerging Therapies in Multiple Sclerosis,arious stages of clinical trials, with several medications presently under regulatory review. New treatments for MS pose exciting opportunities for disease control of relapsing MS; however, new mechanisms of action carry the potential for new side effects, novel adverse events, and the need for vigi
36#
發(fā)表于 2025-3-27 21:47:34 | 只看該作者
37#
發(fā)表于 2025-3-27 22:41:35 | 只看該作者
38#
發(fā)表于 2025-3-28 05:31:02 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 18:00
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
钦州市| 隆安县| 昆明市| 砚山县| 中卫市| 海宁市| 理塘县| 清丰县| 大厂| 宁陵县| 永济市| 云安县| 庆云县| 海晏县| 南安市| 绵竹市| 游戏| 双城市| 万宁市| 金沙县| 镇宁| 赣州市| 江山市| 古交市| 曲周县| 高陵县| 商洛市| 阜新| 德格县| 吴江市| 绍兴县| 太保市| 西安市| 抚远县| 元谋县| 邵东县| 满洲里市| 广河县| 安阳县| 马山县| 海原县|